Oncovin

Also found in: Medical, Financial, Encyclopedia.
(redirected from vincristine sulfate)
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Oncovin - periwinkle plant derivative used as an antineoplastic drug (trade name Oncovin); used to treat cancer of the lymphatic system
vincristine
periwinkle plant derivative - an antineoplastic drug used to treat some forms of cancer
brand, brand name, marque, trade name - a name given to a product or service
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Mentioned in
References in periodicals archive
and its affiliates for which CASI has exclusive rights to the greater China market, consisting of EVOMELA (Melphalan for Injection), ZEVALIN (Ibritumomab Tiuxetan) and MARQIBO (Vincristine Sulfate Liposome Injection) and (iv) a portfolio of FDA-approved and pending abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate (TDF) indicated for the treatment of hepatitis B virus.
CASI Pharmaceuticals Announces Launch of EVOMELA in China
and its affiliates for which CASI has exclusive rights to the greater China market, consisting of EVOMELA[R] (Melphalan for Injection), ZEVALIN[R] (Ibritumomab Tiuxetan) and MARQIBO[R] (Vincristine Sulfate Liposome Injection); and (iv) a portfolio of FDA-approved and pending abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate (TDF) indicated for the treatment of hepatitis B virus.
CASI Pharmaceuticals Announces Launch of EVOMELAA[R] (melphalan for injection) in China
has approved the company's Clinical Trial Application allowing for a registration clinical trial to evaluate the efficacy and safety of vincristine sulfate Liposome injection, Marqibo.
Casi Pharmaceuticals' CTA for Marqibo approved by China's NMPA
Under the deal, Acrotech will acquire products including Fusilev (levoleucovorin), Folotyn (pralatrexate injection), Zevalin (ibritumomab tiuxetan), Marqibo (vinCRIStine sulfate Liposome injection), Beleodaq (belinostat) for injection, Evomela (melphalan) for injection and Khapzory (levoleucovorin).
Acrotech Biopharma to acquire seven FDA-approved haematology/oncology products from Spectrum Pharmaceuticals
Under the sale, the seven US FDA-approved hematology/oncology products include: FUSILEV (levoleucovorin), FOLOTYN (pralatrexate injection), ZEVALIN (ibritumomab tiuxetan), MARQIBO (vinCRIStine sulfate LIPOSOME injection), BELEODAQ (belinostat) for injection, EVOMELA (melphalan) for injection, and KHAPZORY (levoleucovorin).
Spectrum Pharmaceuticals reports divestiture of marketed portfolio to focus on new and innovative therapies for cancer patients
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.